Molekulare Diagnostik des von-Willebrand-Syndroms

Frauke Bergmann; U. Budde; R. Schneppenheim

doi:10.1055/s-0038-1655344

Hämostaseologie, Table of Contents

Hamostaseologie 1998; 18(03): 140-149
DOI: 10.1055/s-0038-1655344

Übersichtsarbeiten/Review Articles

Schattauer GmbH

Molekulare Diagnostik des von-Willebrand-Syndroms

Frauke Bergmann

²Labor Keeser, Arndt & Partner

,

U. Budde

²Labor Keeser, Arndt & Partner

,

R. Schneppenheim

¹Universitätskinderklinik Eppendorf, Abteilung Hämatologie/Onkologie, Hamburg

› Author Affiliations

Abstract

Zusammenfassung

Seit der Erstbeschreibung des von-Willebrand-Syndroms (vWS) im Jahre 1926 durch Erik Adolf von Willebrand als »Hereditär Pseudohemofili« schaffte erst die Verfügbarkeit moderner hämostaseologischer und molekularer Methoden die Voraussetzung für die heutigen Kenntisse über Pathophysiologie und Genetik der zugrundeliegenden quantitativen, qualitativen und molekularen Defekte. Die ausgeprägte Heterogenität der klinischen Symptome und Laborparameter korrespondiert mit der Natur und der Lokalisation molekularer Defekte in definierten Regionen des multifunktionellen von-Willebrand-Faktors (vWF). Die exakte Charakterisierung der betroffenen Patienten mittels konventioneller und spezieller hämostaseologischer Methoden ist die essentielle Voraussetzung für die Auswahl der adäquaten Strategie zur weiteren molekularen Analyse. Das diagnostische Procedere zur Klassifikation und die insbesondere in Deutschland häufigsten Mutationen des von-Willebrand-Faktors werden dargestellt.

Schlüsselwörter

von-Willebrand-Faktor - von-Willebrand-Syndrom - molekulargenetische Diagnostik - molekulare Defekte

Full Text

References

LITERATUR
1 Bahnak BR, Lavergne JM, Rothschild C, Meyer D. A stop codon in a patient with severe type III von Willebrand disease (letter). Blood 1991; 78: 1148-9.
2 Bird AP. DNA méthylation and the frequency of CpG in animal DNA. Nucleic Acids Res 1980; 08: 1499-504.
3 Bonthron D, Orr EC, Mitsock LM, Ginsburg D, Handin RI, Orkin SH. Nucleotide sequence of pre-pro-von Willebrand factor cDNA. Nucleic Acid Res 1986; 14: 7125-7.
4 Budde U, Schäfer G, Müller N, Hammerstein U, Lüchters G. Vorkommen milder Formen des von Willebrand Syndroms Typ I in der »Normalbevölkerung«. In: Hämostase, Thrombophilie und Arteriosklerose. van de Loo J, Asbeck F. (Hrsg.). Stuttgart: Schattauer Verlag; 1982: 505-9.
5 Casonato A, Fabris F, Girolami A. Platelet aggregation and pseudothrombocytopenia induced by l-desamino-8D-arginine vasopressin (DDAVP) in type IIB von Willebrand’s disease. Eur J Haematol 1990; 45: 36-42.
6 De Marco L, Girolami A, Zimmerman TS, Ruggeri ZM. Von Willebrand factor interaction with the glycoprotein IIb/IIIa complex: its role in platelet function as demonstrated in patients with congenital afibrinogenemia. J Clin Invest 1986; 77: 1272-4.
7 Eikenboom JCJ, Ploos HKvan Amstel, Reitsma PH, Briët E. Mutations in severe type III von Willebrand’s disease in the Dutch population: candidate missense and nonsense mutations associated with reduced levels of von Willebrand factor messenger RNA. Thromb Haemost 1992; 68: 448-54.
8 Eriksson AW, Hiepler E, Jürgens R, Lehmann W, Schulz H. Untersuchungen zur Thrombopathie (v. Willebrand-Jürgens). Klin Wochenschr 1961; 39: 32-42.
9 Fay PJ, Kawai Y, Wagner DD, Ginsburg D, Bonthron D, Ohlsson BMWilhelm, Chavin SI, Abraham GN, Handin RI, Orkin SH. Propolypeptide of von Willebrand factor circulates in blood and is identical to von Willebrand factor antigen II. Science 1986; 232: 995-8.
10 Foster PA, Fulcher CA, Marti T, Titani K, Zimmerman TS. A major factor VIII binding domain resides within the amino-terminal 272 amino acid residues of von Willebrand factor. J Biol Chem 1987; 262: 8443-6.
11 Fowler WE, Fretto LJ, Hamilton KK, Erickson HP, McKee PA. Substructure of human von Willebrand factor. J Clin Invest 1985; 76: 1491-500.
12 Fulcher CA, Zimmerman TS. Characterization of the human factor VIII procoagulant protein with a heterologous precipitating antibody. Proc Natl Acad Sci USA 1982; 79: 1648-52.
13 Furlan M. FVIII/von Willebrand factor: a multivalent ligand binding to platelets and collagen. Blut 1986; 52: 329-36.
14 Gaucher C, Jorieux S, Mercier B, Oufkir D, Mazurier C. The »Normandy« variant of von Willebrand disease: characterization of a point mutation in the von Willebrand factor gene. Blood 1991; 77: 1937-41.
15 Gaucher C, Mercier B, Jorieux S, Oufkir D, Mazurier C. Identification of two point mutations in the von Willebrand factor gene of three families with the »Normandy« variant of von Willebrand disease. Br J Haematol 1991; 78: 506-14.
16 Gaucher C, Dieval J, Mazurier C. Characterization of von Willebrand factor gene defects in two unrelated patients with type IIC von Willebrand disease. Blood 1994; 84: 1024-30.
17 Gazda H, Budde U, Krey S, Rokicka-Milewska R, Schneppenheim R. AC in exon 18 of the von Willebrand factor gene is the most common mutation in patients with severe von Willebrand disease type 3 in Poland. Blood 1997; 90 Suppl 1(2): 92b (Abstract).
18 Ginsburg D, Handin RI, Bonthron DT, Donlon TA, Bruns GA, Latt SA, Orkin SH. Human von Willebrand factor (vWF): isolation of complementary DNA (cDNA) clones and chromosomal localization. Science 1985; 228: 1401-6.
19 Ginsburg D, Sadler JE. von Willebrand disease: a database of point mutations, insertions and deletions. Thromb Haemost 1993; 69: 177-84.
20 Girma JP, Meyer D, Verweij CL, Pannekoek H, Sixma JJ. Structure-function relationship of human von Willebrand factor. Blood 1987; 70: 605-11.
21 Hach-Wunderle V, Vigh Z, Scharrer I. Diagnostik und Therapie des von Willebrand Syndroms. Med Welt 1987; 38: 1654-7.
22 Hensen A, Mattem MJ, Loeliger EAH. Haemophilia A with apparently autosomal dominant inheritance: Evidence of a second autosomal locus involved in factor VIII production. Thromb Diath Haemorrh 1965; 14: 341-5.
23 Hillery CA, Mancuso DJ, Sadler JE, Ponder JW, Joswiak MA, Christopherson PA, Gill JC, Scott JP, Montgomery RR. Type 2M von Willebrand disease: F606I and I662F mutations in the glycoprotein lb binding domain selectively impair ristocetin but not botrocetin-mediated binding of von Willebrand factor to platelets. Blood 1998; 91: 1572-81.
24 Holmberg L, Dent JA, Schneppenheim R, Budde U, Ware J, Ruggeri ZM. von Willebrand factor mutation enhancing interaction with platelets in patients with normal multimeric structure. J Clin Invest 1993; 91: 2169-77.
25 Holmberg L, Karpman D, Isaksson C, Kristoffersson C, Lethargen S, Schneppenheim R. Ins405AsnPro Mutation in the von Willebrand factor propeptide in recessive type 2A (IIC) von Willebrand’s disease. Thromb Haemost 1998; 79: 718-22.
26 Hoyer LW, Los RPDSantos, Hoyer JR. Antihemophilic factor antigen. Localization in endothelial cells by immunoflorecent microscopy. J Clin Invest 1973; 52: 2737-44.
27 http://mmg2.im.med.umich.edu/vWF/
28 Jaffe EA, Hoyer LW, Nachman RL. Synthesis of von Willebrand factor by cultured human endothelial cells. Proc Natl Acad Sci USA 1974; 71: 1906-9.
29 Jorieux S, Tuley EA, Gaucher C, Mazurier C, Sadler JE. The mutation Arg (53)-Trp causes von Willebrand disease Normandy by abolishing binding to FVIII. Studies with recombinant von Willebrand factor. Blood 1992; 79: 563-7.
30 Kroner PA, Friedman KD, Fahs SA, Scott JP, Montgomery RR. Abnormal binding of factor VIII is linked with the substitution of glutamine for arginine 91 in von Willebrand factor in a variant form of von Willebrand disease. J Biol Chem 1991; 266: 19146-9.
31 Lenk H, Nilsson IM, Holmberg L, Weissbach G. Frequency of different types of von Willebrand’s disease in the GDR. Acta Med Scand 1988; 224: 275-80.
32 Lynch DC, Williams R, Zimmerman TS, Kirby EP, Livingston DM. Biosynthesis of subunits of factor VIIIR by bovine aortic endothelial cells. Proc Natl Acad Sci USA 1983; 80: 2738-42.
33 Lyons SE, Bruck ME, Bowie EJW, Ginsburg D. Impaired intracellular transport produced by a subset of type IIA von Willebrand disease mutations. J Biol Chem 1992; 267: 4424-30.
34 Mannucci PM, Bloom AL, Larrieu MJ, Nilsson IM, West RR. Artherosclerosis and von Willebrand factor. I. Prevalence of severe von Willebrand’s disease in western Europe and Israel. Br J Hematol 1984; 57: 163-9.
35 Manusco DJ, Tuley EA, Westfield LA, Worrall NK, Shelton BBInloes, Sorace JM, Alevy YG, Sadler JE. Structure of the gene for human von Willebrand factor. J Biol Chem 1989; 264: 19514-27.
36 Manusco DJ, Tuley EA, Westfield LA, Lester TLManusco, LeBeau MM, Sorace JM, Sadler JE. Human von Willebrand factor gene and pseudogene: structural analysis and differentiation by polymerase chain reaction. Biochemistry 1991; 30: 253-69.
37 Mancuso DJ, Montgomery RR, Adam P. The identification of a candidate mutation in the von Willebrand factor gene of patients with a variant form of type I von Willebrand disease. Blood 1991; 78 (Suppl. 01) 67a.
38 Mauz-Körholz C, Budde U, Kruck H, Körholz D, Göbel U. Mangement of severe chronic thrombocytopenia in von Willebrand’s disease type 2B. Arch Dis Child 1998; 78: 257-60.
39 Mayadas TN, Wagner DD. Vicinal Cysteines in the prosequence play a role in von Willebrand factor multimer assembly. Proc Natl Acad Sci USA 1992; 89: 3531-5.
40 Mazurier C. von Willebrand disease masquerading as hemophilia A. Thromb Haemost 1992; 67: 391-6.
41 Mazurier C, Gaucher C, Jorieux S, Goudemand M. the Collaborative Group. Biological effect of desmopressin in eight patients with type 2N (»Normandy«) von Willebrand disease. Br J Hematol 1994; 88: 849-54.
42 Myers RM, Lumelsky N, Lerman LS, Maniatis T. Detection of single base substitutions in total genomic DNA. Nature 1985; 313: 495-8.
43 Ngo KY, Glotz VT, Koziol JA, Lynch DC, Gitschier J, Ranieri P, Ciavarella N, Ruggeri ZM, Zimmerman TS. Homozygous and heterozygous deletions of the von Willebrand factor gene in patients and carriers of severe von Willebrand disease. Proc Natl Acad Sci USA 1988; 85: 2753-7.
44 Nishino M, Girma JP, Rothschild C, Fressinaud E, Meyer D. New variant of von Willebrand disease with defective binding to factor VIII. Blood 1989; 74: 1591-9.
45 Orita M, Iwahana H, Kanazawa H, Hayashi K, Sekiya T. Detection of polymorphisms of human DNA by gel electrophoresis as single-strand conformation polymorphisms. Proc Natl Acad Sci USA 1989; 86: 2766-70.
46 Peake IR, Liddell MB, Moodie P, Standen G, Manusco DJ, Tuley EA, Westfield LA, Sorace JM, Sadler JE, Verweij CL, Bloom AL. Severe type III von Willebrand’s disease caused by deletion of exon 42 of the von Willebrand factor gene: family studies that identify carriers of the condition and a compound heterozygous individual. Blood 1990; 75: 654-61.
47 Rabinowitz I, Tuley EA, Mancuso DJ, Randi AM, Firkin BG, Howard MA, Sadler JE. von Willebrand disease type B: a missense mutation selectively abolishes ristocetin-induced von Willebrand factor binding to platelet gylcoprotein Ib. Proc Natl Acad Sci USA 1992; 89: 9846-9.
48 Randi AM, Rabinowitz I, Mancuso DJ, Mannucci PM, Sadler JE. Molecular basis of von Willebrand disease type IIB Candidate mutations cluster in one disulfide loop between proposed platelet Glycoprotein Ib binding sequences. J Clin Invest 1991; 87: 1220-6.
49 Rodeghiero F, Castaman GC, Dini E. Epidemiological investigation of the prevalence of von Willebrand’s disease. Blood 1987; 69: 454-9.
50 Ruggeri ZM, Pareti FI, Mannucci PM, Ciavarella N, Zimmerman TS. Hightened interaction between platelets and factor VIII/von Willebrand factor in a new subtype of von Willebrand’s disease. New Engl J Med 1980; 302: 1047-51.
51 Ruggeri ZM. Classification of von Willebrand disease. In: Thrombosis and Hemostasis 1987. Verstraete M, Vermylen J, Lijnen R, Arnout J. (Hrsg.). Leuven: Leuven University Press; 1987: 419-45.
52 Sadler JE, Shelton-Inloes BB, Sorace JM, Titani K. Cloning of cDNA and genomic DNA for human von Willebrand factor. Cold Spring Harbor Symposia on Quantitative Biology 1986; 51: 515-23.
53 Sadler JE. A revised classification of von Willebrand disease. Thromb Haemost 1994; 71: 520-5.
54 Sadler EJ, Gralnick HR. Commentary: A new classification for von Willebrand disease. Blood 1994; 84: 676-9.
55 Sakariassen KS, Nievelstein PF, Coller BS, Sixma JJ. The role of platelet membrane glycoproteins Ib and IIb-IIIa in platelet adherence to human artery subendothelium. Br J Haematol 1986; 63: 681-91.
56 Sankarankutty M, Evans D. Chronic arthropathy in von Willebrand’s disease. Clin Lab Haemat 1983; 05: 149-51.
57 Santoro SA. Adsorption of von Willebrand factor/factor VIII by the genetically distinct interstitial collagens. Thromb Res 1981; 21: 689-91.
58 Schneppenheim R, Krey S, Bergmann F, Bock D, Budde U, Lange M, Linde R, Mittler U, Meili E, Mertes G, Olek K, Plendl H, Simeoni E. Genetic heterogeneity of severe von Willebrand disease type III in the German population. Hum Genet 1994; 94: 640-52.
59 Schneppenheim R, Thomas KB, Krey S, Budde U, Jessat U, Sutor AH, Zieger B. Identification of a candidate missense mutation in a family with von Willebrand disease type IIC. Hum Genet 1995; 95: 681-6.
60 Schneppenheim R, Budde U, Krey S, Drewke E, Bergmann F, Lechler E, Oldenburg J, Schwaab R. Results of a screening for von Willebrand disease type 2N in patients with suspected haemophilia A or von Willebrand disease type 1. Thromb Haemost 1996; 76: 598-602.
61 Schneppenheim R, Brassard J, Krey S, Budde U, Kunicki TJ, Holmberg L, Ware J, Ruggeri ZM. Defective dimerization of von Willebrand Faktor subunits due to a CysArg mutation in type HD von Willebrand disease. Proc Natl Acad Sci 1996; 93: 3581-6.
62 Shelton-Inloes BB, Broze GJJ, Miletich JP, Sadler JE. Evolution of human von Willebrand factor: cDNA sequence polymorphisms, repeated domains and relationship to von Willebrand factor antigen II. Biochem Biophys Res Commun 1987; 144: 657-65.
63 Southern EM. Detection of specific sequences among DNA fragments separated by gel electrophoresis. J Mol Biol 1975; 98: 503-17.
64 Sporn LA, Marder VJ, Wagner DD. Inducible secretion of large, biologically potent von Willebrand factor multimers. Cell 1986; 46: 185-90.
65 Titani K, Kumar S, Takio K, Ericsson LH, Wade RD, Ashida K, Walsh KA, Chopek MW, Sadler JE, Fujikawa K. Amino acid sequence of human von Willebrand factor. Biochemistry 1986; 25: 3171-84.
66 Tuley EA, Gaucher C, Jorieux S, Worrall NK, Sadler JE, Mazurier C. Expression of von Willebrand factor “Normandy”: an autosomal mutation that mimics hemophilia A. Proc Natl Acad Sci USA 1991; 88: 6377-81.
67 Vehar GA, Davie EW. Preparation and properties of bovine factor VIII (antihemophilic factor). Bicochemistry 1980; 19: 401-10.
68 von Willebrand EA. Hereditär Pseudohemophili. Finska Läk Sallsk Handl 1926; 68: 87-112.
69 von Willebrand EA, Jürgens R. Über ein neues vererbbares Blutungsübel: die konstitutionelle Thrombopathie. Dtsch Arch Klin Med 1933; 175: 453-83.
70 Wagner DD, Marder VJ. Biosynthesis of von Willebrand protein by human endothelial cells. Identification of a large precursor polypeptide chain. J Biol Chem 1983; 258: 2065-7.
71 Wagner DD, Marder VJ. Biosynthesis of von Willebrand protein by human endothelial cells: processing steps and their intracellular localisation. J Cell Biol 1984; 99: 2123-30.
72 Zhang ZP, Lindstedt M, Falk G, Blombäck M, Egberg N, Anvret M. Nonsense mutations of the von Willebrand factor gene in patients with von Willebrand disease type III and type I. Am J Hum Genet 1992; 51: 850-8.
73 Zhang ZP, Falk G, Blombäck M, Egberg N, Anvret M. A single cytosine deletion exon 18 of the von Willebrand factor gene is the most common mutation in Swedish vWD type III patients. Hum Mol Genet 1992; 01: 757-8.
74 Zhang ZP, Blombäck M, Nyman D, Anvret M. Mutations of von Willebrand factor gene in families with von Willebrand disease in the Aland Islands. Proc Natl Acad Sci USA 1993; 90: 7937-40.
75 Zimmerman TS, Ratnoff OD, Powell AE. Immunologic differentiation of classic hemophilia (factor VIII deficieny) and von Willebrand’s disease, with observations on combined deficiencies of antihemophilic factor and proaccelerin (factor V) and on an acquired circulating anticoagulant against antihemophilic factor. J Clin Invest 1971; 50: 244-54.
76 Zucker MB, Broekman MJ, Kaplan KL. Factor VIII-related antigen in human blood platelets. Localization and release by thrombin and collagen. J Lab Clin Med 1979; 94: 675-82.